ASH 2024 | Dr. JingZhou Hou Highlights CAHON Winter Symposium and Shares Key Research Presented at ASH

ASH 2024 | Dr. JingZhou Hou Highlights CAHON Winter Symposium and Shares Key Research Presented at ASH

The 66th Annual Meeting of the American Society of Hematology (ASH) successfully concluded in San Diego, USA, from December 7–10, 2024. As the largest and most comprehensive international academic conference in the field of hematology, it attracts global experts and scholars each year to discuss and exchange views on the latest research advancements. During this year’s ASH meeting, the Chinese American Hematologist and Oncologist Network (CAHON) successfully held its Winter Symposium. Hematology frontier invited Dr. JingZhou Hou, CAHON President and a professor at the University of Pittsburgh Medical Center, to share insights on CAHON’s founding mission, highlights from this Winter Symposium, and details of his three research studies (including one oral presentation and two posters) presented at ASH.
Dr. Jun Zhou: Lessons from 29 Protocol Revisions in the CheckMate649 Study – A Blueprint for Clinical Trial Design in Immunotherapy

Dr. Jun Zhou: Lessons from 29 Protocol Revisions in the CheckMate649 Study – A Blueprint for Clinical Trial Design in Immunotherapy

To advance the standard of care for gastrointestinal cancers in China and share the latest developments and insights, the "2024 CSCO Workshop on Standardized Diagnosis and Treatment of Gastrointestinal Cancers," co-hosted by the Chinese Society of Clinical Oncology (CSCO), the Beijing Xisike Clinical Oncology Research Foundation, and the Hangzhou Oriental Clinical Oncology Research Center, took place in Shanghai from August 17–18, 2024.
ESMO Asia 2024 | Prof. Zhi Peng Deciphers DESTINY-Gastric06: ADCs Usher in a New Era for Advanced HER2-Positive Gastric Cancer Treatment

ESMO Asia 2024 | Prof. Zhi Peng Deciphers DESTINY-Gastric06: ADCs Usher in a New Era for Advanced HER2-Positive Gastric Cancer Treatment

From December 6–8, 2024, the ESMO Asia Annual Meeting was held in Singapore, presenting groundbreaking research in oncology. Among the key highlights was the DESTINY-Gastric06 (DG06) study, which sparked extensive discussion. Oncology Frontier invited Prof. Zhi Peng, a leading researcher and specialist from Peking University Cancer Hospital, to share the latest findings from the DG06 study and insights into the role and future potential of antibody-drug conjugates (ADCs) in cancer treatment.
SABCS 2024 | Special Session: Exploring Genetic Variants Linked to Hereditary Breast Cancer Risk

SABCS 2024 | Special Session: Exploring Genetic Variants Linked to Hereditary Breast Cancer Risk

Pathogenic germline mutations in certain genes are known to increase the risk of hereditary breast cancer. Approximately 5% to 10% of all breast cancer cases are hereditary, primarily driven by such mutations, with BRCA1/2 being the most common. Germline mutations also guide treatment decisions, as patients with pathogenic BRCA1/2 germline mutations may benefit from PARP inhibitor-based therapies.
TOUCH Study – Breakthroughs and Limitations in Chemotherapy-Free Neoadjuvant Therapy for HR+/HER2+ Breast Cancer

TOUCH Study – Breakthroughs and Limitations in Chemotherapy-Free Neoadjuvant Therapy for HR+/HER2+ Breast Cancer

Treatment strategies for HR+/HER2+ breast cancer have long been a focus of research. On December 11 (Central Time), during the 47th San Antonio Breast Cancer Symposium (SABCS), the results of the TOUCH study (Abstract RF1-02) were released, drawing significant attention. This international, open-label Phase II trial explored the efficacy of a chemotherapy-free approach in the neoadjuvant treatment of early HR+/HER2+ breast cancer. Dr. Feng Jin (The First Hospital of China Medical University), Dr. Diandong Zhang (Zhongshan Hospital, Dalian University), and Dr. Xinmiao Yu (The First Hospital of China Medical University) were invited to provide in-depth commentary on the study.
SABCS 2024 | Dr. Zhenzhen Liu: Optimizing Neoadjuvant and Adjuvant Treatment Strategies for HR+/HER2+ Early Breast Cancer in China Through Real-World

SABCS 2024 | Dr. Zhenzhen Liu: Optimizing Neoadjuvant and Adjuvant Treatment Strategies for HR+/HER2+ Early Breast Cancer in China Through Real-World

The 47th San Antonio Breast Cancer Symposium (SABCS) will be held from December 10 to 13, 2024, in San Antonio, USA. As one of the largest and most prestigious scientific gatherings in breast cancer research, SABCS showcases the latest research findings, clinical practices, treatment advancements, and technological innovations in breast cancer from the past year.
ESMO Asia 2024 | Professor Ming Cao on Bladder-Sparing Strategies Combining Local Surgery and Chemoradiotherapy for MIBC Patients

ESMO Asia 2024 | Professor Ming Cao on Bladder-Sparing Strategies Combining Local Surgery and Chemoradiotherapy for MIBC Patients

Radical cystectomy remains the standard treatment for muscle-invasive bladder cancer (MIBC), but many patients express a strong desire to preserve their bladder. To address this, various bladder-sparing strategies have been explored, including transurethral resection of bladder tumor (TURBT), partial cystectomy (PC), chemotherapy, radiotherapy, and surveillance. At the recent ESMO Asia Annual Meeting, Professor Ming Cao from Renji Hospital, Shanghai Jiao Tong University School of Medicine, presented his research on bladder preservation through postoperative adjuvant therapy for MIBC. Urology Frontier had the opportunity to discuss his findings with him on-site.

ESMO Asia 2024 | Early Trials Show Favorable Benefit-Risk Profiles for Oral Small-Molecule PD-L1 Inhibitor

At the 2024 ESMO Asia Congress “Preferred Oral Presentations - Development and Precision Medicine” session, two oral immune checkpoint inhibitors (ICIs) for solid tumors demonstrated initial efficacy and manageable safety in early-phase trials. These results support further development of novel small-molecule PD-L1 inhibitors, which offer favorable benefit-risk profiles and better usability compared to antibody-based ICIs.
ISRELC 2024 | Dr. You Lu: Transformative Clinical Research in Adaptive Immuno-Radiotherapy

ISRELC 2024 | Dr. You Lu: Transformative Clinical Research in Adaptive Immuno-Radiotherapy

With the development of immune checkpoint inhibitors (ICIs) and the widespread application of immunotherapy, the treatment paradigm for driver mutation-negative lung cancer has been fundamentally transformed. Multiple studies have demonstrated that radiotherapy (RT) can regulate both local and systemic immune responses, triggering anti-tumor immune effects. As a result, the immunomodulatory properties of RT and its synergistic effects when combined with immunotherapy have garnered significant attention within the medical community.